Positive psychology support for survivors of stem cell transplants
Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors
This study is testing a new program that helps people who have had stem cell transplants feel happier and less anxious by encouraging them to do enjoyable activities.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Brigham and Women's Hospital Academic / other |
| Locations | 3 sites (Tampa, Florida and 2 other locations) |
| Trial ID | NCT06328127 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of a positive psychology intervention called PATH on improving anxiety, depression, and quality of life in survivors of hematopoietic stem cell transplantation (HSCT). The intervention is designed for patients who are 100 days post-transplant and focuses on encouraging enjoyable activities to enhance positive emotions. Participants will be compared to a control group receiving usual care, with outcomes measured using validated assessment tools. The study aims to address the psychological needs of HSCT survivors during their recovery phase.
Who should consider this trial
Good fit: Ideal candidates are adult patients aged 18 and older who are undergoing allogeneic HSCT and are approaching 100 days post-transplant.
Not a fit: Patients who underwent HSCT for benign conditions or those with severe psychiatric or cognitive impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve the mental health and overall quality of life for HSCT survivors.
How similar studies have performed: Other studies have shown promising results with psychological interventions in similar patient populations, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (aged 18 years and older) undergoing allogeneic HSCT and are approaching 100-days post-HSCT * Ability to speak, read, and respond to questions in English or Spanish to complete study procedures * Access to a basic telephone Exclusion Criteria: * Patients who underwent allogeneic HSCT for benign hematologic conditions * Patients with severe psychiatric or cognitive conditions, such as dementia, determined by their transplant oncologist to make them unable to provide informed consent or comply with study procedures
Where this trial is running
Tampa, Florida and 2 other locations
- Moffitt Cancer Center — Tampa, Florida, United States (Recruiting)
- Dana Farber Cancer Institute — Boston, Massachusetts, United States (Recruiting)
- Duke Cancer Institute — Durham, North Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Hermioni Amonoo, MD, MPP, MPH — Brigham and Women's Hospital
- Study coordinator: Hermioni Amonoo, MD, MPP, MPH
- Email: hermioni_amonoo@dfci.harvard.edu
- Phone: 617-525-7472
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.